Noble metal-dithiocarbamates precious allies in the fight against cancer

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 12, 2012, Pages 1216-1229

  Márta, Eszter ^a   Ronconi, Luca ^a   Nardon, Chiara ^a   Fregona, Dolores ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticancer agents; Copper; Dithiocarbamato complexes; Gold; Metal based drugs; Palladium; Platinum; Ruthenium

Indexed keywords

ALLOCHRYSINE; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; BETA LACTAM ANTIBIOTIC; CARBOPLATIN; CISPLATIN; COPPER COMPLEX; DIMETHYLDITHIOCARBAMIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DITHIOCARBAMIC ACID COPPER COMPLEX; DITHIOCARBAMIC ACID DERIVATIVE; DITHIOCARBAMIC ACID GOLD COMPLEX; DITHIOCARBAMIC ACID PALLADIUM COMPLEX; DITHIOCARBAMIC ACID PLATINUM COMPLEX; DITHIOCARBAMIC ACID RUTHENIUM COMPLEX; ETHYLSARCOSINEDITHIOCARBAMATE; FOSINOPRIL; GOLD COMPLEX; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; METAL COMPLEX; PALLADIUM COMPLEX; PEPTIDOMIMETIC AGENT; PLATINUM COMPLEX; PYRROLIDINE DITHIOCARBAMATE; RUTHENIUM COMPLEX; SODIUM AUROTHIOSULFATE; TERT BUTYLSARCOSINEDITHIOCARBAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; ZIDOVUDINE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COLORECTAL CARCINOMA; COMPLEX FORMATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG ACTIVITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EHRLICH ASCITES TUMOR; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CORTEX; NONHUMAN; PHARMACODYNAMICS; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; COORDINATION COMPLEXES; COPPER; GOLD; HUMANS; NEOPLASMS; PALLADIUM; PLATINUM; RUTHENIUM; THIOCARBAMATES;

EID: 84866461459     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762004     Document Type: Review

References (111)

1. Lippert, B. Impact of Cisplatin on the recent development of Pt coordination chemistry: a case study. Coord. Chem. Rev., 1999, 182, 263-295.
2. Boulikas, T.; Pantos, A.; Bellis, E.; Christofis, P. Designing platinum compounds in cancer: structures and mechanisms. Cancer Therapy, 2007, 5, 537-583.
3. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nature Rev. Cancer, 2007, 7, 573-584.
4. Reedijk, J. Metal-ligand exchange kinetics in platinum and ruthenium complexes. Platinum Metals Rev., 2008, 52, 2-11.
5. van Rijt, S.H.; Sadler, P.J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov. Today, 2009, 14, 1089-1097.
6. Keppler, B.K. Metal Complexes in Cancer Chemotherapy, VCH: Weinheim, 1993.
7. Berners-Price, S.J.; Filipovska, A. Gold compounds as therapeutic agents for human diseases. Metallomics, 2011, 3, 863-873.
8. Sava, G.; Bergamo, A.; Dyson, P.J. Metal-based antitumour drugs in the post-genomic era: what comes next? Dalton Trans., 2011, 40, 9069-9075.
9. Tardito, S.; Marchiò, L. Copper compounds in anticancer strategies. Curr. Med. Chem., 2009, 16, 1325-1348.
10. Frezza, M.; Hindo, S.; Chen, D.; Davenport, A.; Schmitt, S.; Tomco, D.; Dou, P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Design, 2010, 16, 1813-1825.
11. Messori L.; Marcon G. Gold complexes in the treatment of rheumatoid arthritis. Met. Ions Biol. Syst., 2004, 279-304.
12. Kostova, I. Gold coordination complexes as anticancer agents. Anti-Cancer Agents Med. Chem., 2006, 6, 19-32.
13. Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord. Chem. Rev., 2009, 253, 1670-1681.
14. Tiekink, E.R.T. Anti-cancer potential of gold complexes. Inflammopharmacology, 2008, 16, 138-142.
15. Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.; Messori, L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Chem. Rev., 2010, 30, 550-580.
16. Clarke, M.J.; Zhu, F.; Frasca, D.R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev., 1999, 99, 2511-2533.
17. Allardyce, C.S.; Dyson, P.J. Ruthenium in medicine: current clinical uses and future prospects. Platinum Metals Rev., 2001, 45, 62-69.
18. Levina, A.; Mitra, A.; Lay, P.A. Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1, 458-470.
19. Pacor, S.; Zorzet, S.; Cocchietto, M.; Bacac, M.; Vadori, M.; Turrin, C.; Gava, B.; Castellarin, A.; Sava, G. Intratumoral NAMIA treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment. J. Pharmacol. Exp. Ther., 2004, 310, 737-744.
20. Hartinger, C.G.; Zorbas-Seifried, S.; Jakupec, M.A.; Kynast, B.; Zorbas, H.; Keppler, B.K. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100, 891-904.
21. Hartinger, C.G.; Jacupec, M.A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P.J.; Keppler, B.K. KP1019, A new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodivers., 2008, 5, 2140-2155.
22. Ronconi, L.; Fregona, D. The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes. Dalton Trans., 2009, 10670-10680.
23. Cattaruzza, L.; Fregona, D.; Mongiat, M.; Ronconi, L.; Fassina, A.; Colombatti, A.; Aldinucci, D. Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts. Int. J. Cancer, 2011, 128, 206-215.
24. Marzano, C.; Ronconi, L.; Chiara, F.; Giron, M.C.; Faustinelli, I.; Cristofori, P.; Trevisan, A.; Fregona, D. Gold(III)-dithiocarbamato anticancer agents: activity, toxicology and histopathological studies in rodents. Int. J. Cancer, 2011, 129, 487-496.
25. Wang, X.; Guo, Z. The role of sulfur in platinum anticancer chemotherapy. Anti-Cancer Agents Med. Chem., 2007, 7, 19-34.
26. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int., 2008, 73, 994-1007.
27. Dorr, R.T. in: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2; Pinedo, H.M.; Schornagel, J.H. Eds.; Plenum Press: New York, 1996, pp. 131-154.
28. Borch, R.F.; Dedon, P.C.; Gringeri, A.; Montine, T.J. in: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Nicolini, M. Ed., Martinus Nijoff Publishing: Boston, 1988, 216-281.
29. Segovia, N.; Crovetto, G.; Lardelli, P.; Espigares, M. In vitro toxicity of several dithiocarbamates and structure-activity relationships. J. Appl. Toxicol., 2002, 22, 353-357.
30. Kelland, L.R. Overcoming resistance to platinum therapy in patients with advanced cancer. Am. J. Cancer, 2002, 1, 247-255.
31. Faraglia, G.; Fregona, D.; Sitran, S.; Giovagnini, L.; Marzano, C.; Baccichetti, F.; Casellato, U.; Graziani, R. Platinum(II) and palladium(II) complexes with dithiocarbamates and amines: synthesis, characterization and cell assay. J. Inorg. Biochem., 2001, 83, 31-40.
32. Trevisan, A.; Marzano, C.; Cristofori, P.; Borella Venturini, M.; Giovagnini, L.; Fregona, D. Synthesis of a palladium(II)-dithiocarbamate complex: biological assay and nephrotoxicity in rats. Arch. Toxicol., 2002, 76, 262-268.
33. Fregona, D.; Giovagnini, L.; Ronconi, L.; Marzano, C.; Trevisan, A.; Sitran, S.; Biondi, B.; Bordin, F. Pt(II) and Pd(II) derivatives of ter-butylsarcosinedithiocarbamate: synthesis, chemical and biological characterization and in vitro nephrotoxicity. J. Inorg. Biochem., 2003, 93, 181-189.
34. Alverdi, V.; Giovagnini, L.; Marzano, C.; Seraglia, R.; Bettio, F.; Sitran, S.; Graziani, R.; Fregona, D. Characterization studies and cytotoxicity assays of Pt(II) and Pd(II) dithiocarbamate complexes by means of FT-IR, NMR spectroscopy and mass spectrometry. J. Inorg. Biochem., 2004, 98, 1117-1128.
35. Giovagnini, L.; Marzano, C.; Bettio, F.; Fregona, D. Mixed complexes of Pt(II) and Pd(II) with ethylsarcosinedithiocarbamate and 2-/3-picoline as antitumor agents. J. Inorg. Biochem., 2005, 99, 2139-2150.
36. Andrews, P.A.; Velury, S.; Mann, S.C.; Howell, S.B. Cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 1988, 48, 68-73.
37. Marzano, C.; Fregona, D.; Baccichetti, F.; Trevisan, A.; Giovagnini, L.; Bordin, F. Cytotoxicity and DNA damage induced by a new platinum(II) complex with pyridine and dithiocarbamate. Chem.-Biol. Interact., 2002, 140, 215-229.
38. Gately, D.P.; Howell, S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer, 1993, 67, 1171-1176.
39. Johnson, N.P.; Butour, J.L.; Villani, G.; Wimmer, F.L.; Defais, M.; Pierson, V.; Brabec, V. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog. Clin. Biochem. Med., 1989, 10, 1-24.
40. Marzano, C.; Bettio, F.; Baccichetti, F.; Trevisan, A.; Giovagnini, L.; Fregona, D. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Chem.-Biol. Interact., 2004, 148, 37-48.
41. Marzano, C.; Trevisan, A.; Giovagnini, L.; Fregona, D. Synthesis of a new platinum(II) complex: anticancer activity and nephrotoxicity in vitro. Toxicol. in Vitro, 2002, 16, 413-419.
42. Crisyofori, P.; Zanetti, E.; Fregona, D.; Piaia, A.; Trevisan, A. Renal proximal tubule segment-specific nephrotoxicity: an overview on biomarkers and histopathology. Toxicol. Pathol., 2007, 35, 270-275.
43. Roat-Malone, R.M. Bioinorganic chemistry: a short course. Wiley Interscience, 2002.
44. Weiss, K.C.; Linder, M.C. Copper transport in rats involving a new plasma protein. Am. J. Physiol-Endocrinol. Met., 1985, 249, 77-88.
45. Hill, G.M.; Link, J.E. Transporters in the absorption and utilization of zinc and copper. J. Animal Sci., 2009, 87, 85-89.
46. Gregoriadis, G.C.; Apostolidis, N.S.; Romanos, A.N.; Paradellis, T.P. A comparative study of trace elements in normal and cancerous colorectal tissues. Cancer, 1983, 52, 508-519.
47. Apelgot, S.; Coppey, J.; Fromentin, A.; Guille, E.; Poupon, M.F.; Roussel, A. Altered distribution of copper (64Cu) in tumor-bearing mice and rats. Anticancer Res., 1986, 6, 159-164.
48. Coates, R.J.; Weiss, N.S.; Daling, J.R.; Rettmer, R.L.; Warnick, G.R. Cancer risk in relation to serum copper levels. Cancer Res., 1989, 49, 4353-4356.
49. Gupta, S.K.; Shukla, V.K.; Vaidya, M.P.; Roy, S.K.; Gupta, S. Serum trace elements and Cu/Zn ratio in breast cancer patients. J. Surg. Oncol., 1991, 46, 178-181.
50. McAuslan, B.R.; Reilly, W. Endothelial cell phagokinesis in response to specific metal ions. Exp. Cell Res., 1980, 130, 147-157.
51. Lowndes, S.A; Harris, A.L. Copper chelation as an antiangiogenic therapy. Oncol. Res., 2004, 14, 529-539.
52. Hu, G. Copper stimulates proliferation of human endothelial cells under culture. J. Cell Biochem., 1998, 69, 326-335.
53. Fox, S.B.; Gasparini, G.; Harris, A.L. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet. Oncol., 2001, 2, 278-289.
54. Pan, Q.; Klerr, C.G.; Van Golen, K.L.; Irani, J.; Bottema, K.M.; Bias, C.; De Carvalho, M.; Mesri, E.A.; Robins, D.M.; Dick, R.D.; Brere, G.J.; Merajver, S.D. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res., 2002, 62, 4854-4859.
55. Chen, D.; Dou, Q.P. New uses for old copper-binding drugs: Converting the pro-angiogenic copper to a specific cancer cell death inducer. Exp. Opinion Ther. Targets, 2008, 12, 739-748.
56. Kenyon, G.D.; Kuhn, D.J.; Aslamuzzaman, K.; Dou, Q.P. Antiangiogenic and anti-tumor properties of proteasome inhibitors. Curr. Cancer Drug Targets, 2005, 5, 529-541.
57. Giovagnini, L.; Sitran, S.; Montopoli, M.; Caparrotta, L.; Corsini, M.; Rosani, C.; Zanello, P.; Dou, Q.P.; Fregona, D. Chemical and biological profiles of novel copper(II) complexes containing Sdonor ligands for the treatment of cancer. Inorg. Chem., 2008, 47, 6336-6343.
58. Parodi, F.E.; Mao, D.; Ennis, T.L.; Bartoli, M.A.; Thompson, R.W. Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J. Vasc. Surg., 2005, 41(3), 479-489.
59. Milacic, V.; Chen, D.; Giovagnini, L.; Diez, A.; Fregona, D.; Dou, Q.P. Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol. Appl. Pharmacol., 2008, 231, 24-33.
60. Cvek, B.; Milacic, V.; Taraba, J.; Dou, Q.P. Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J. Med. Chem., 2008, 51, 6256-6258.
61. Habib, F.K.; Dembinski, T.C.; Stitch, S.R. The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin. Chim. Acta, 1980, 104, 329-335.
62. Nayak, S.B.; Bhat, V.R.; Upadhyay, D.; Udupa, S.L. Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J. Physiol. Pharmacol., 2003, 47, 108-110.
63. Kuo, H.W.; Chen, S.F.; Wu, C.C.; Chen, D.R.; Lee, J.H. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol. Trace Elem. Res., 2002, 89, 1-11.
64. Rizk, S.L.; Sky-Peck, H.H. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res., 1984, 44, 5390-5394.
65. Diez, M.; Arroyo, M.; Cerdan, F.J.; Munoz, M.; Martin, M.A.; Balibrea, J.L. Serum and tissue trace metal levels in lung cancer. Oncology, 1989, 46, 230-234.
66. Turecky, L.; Kalina, P.; Uhlikova, E.; Namerova, S.; Krizko, J. Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin. Wochenschr., 1984, 62, 187-189.
67. Chen, D.; Cui, Q.C.; Yang, H.; Dou, Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res., 2006, 66, 10425-10433.
68. Krampe, H.; Stawicki, S.; Wagner, T.; Bartels, C.; Aust, C.; Ruther, E.; Poser, W.; Ehrenreich, H. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol. Clin. Exp. Res., 2006, 30, 86-95.
69. Sunderman, F.W. Therapeutic properties of sodium diethyldithiocarbamate: its role as an inhibitor in the progression of AIDS. Ann. Clin. Lab. Sci., 1991, 21, 70-81.
70. Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl., 1992, 369, 15-26.
71. Hersh, E.M.; Brewton, G.; Abrams, D.; Bartlett, J.; Galpin, J.; Gill, P.; Gorter, R.; Gottlieb, M.; Jonikas, J.J.; Landesman, S.; Levine, A.; Marcel, A.; Petersen, E.A.; Whiteside, M.; Zahradnik, J.; Negron, C.; Boutitie, F.; Caraux, J.; Dupuy, J.-M.; Salmi, L.R. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, doubleblind, placebo-controlled, multicenter study. JAMA, 1991, 265, 1538-1544.
72. Brar, S.S.; Grigg, C.; Wilson, K.S.; Holder, W.D.; Dreau, D.; Austin, C.; Foster, M.; Ghio, A.J.; Whorton, A.R.; Stowell, G.W.; Whittall, L.B.; Wittle, R.R.; White, D.P.; Kennedy, T.P. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metaldependent manner in vitro, in mice and in patient with metastatic disease. Mol. Cancer Ther., 2004, 3, 1049-1060.
73. Cen, D.; Brayton, D.; Shahandeh, B.; Meyskens, F.L.; Farmer, P.J. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J. Med. Chem., 2004, 47, 6914-6920.
74. Pang, H.; Chen, D.; Cui, Q.C.; Dou, Q.P. Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosis-inducing activities in cancer cells. Int. J. Mol. Med., 2007, 19, 809-816.
75. Daniel, K.G.; Chen, D.; Orlu, S.; Cui, Q.C.; Miller, F.R.; Dou, Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibit tors and apoptosis inducers in human breast cancer cells. Breast Cancer Res., 2005, 7, R897-R908.
76. Chen, D.; Peng, F.; Cui, Q.C.; Daniel, K.G.; Orlu, S.; Liu, J.; Dou, Q.P. Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci., 2005, 10, 2932-2939.
77. Chen, J.; Du, C.; Kang, J.; Wang, J. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis. Chem.-Biol. Interact., 2008, 171, 26-36.
78. Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem., 2006, 13, 1085-1107.
79. Rademaker-Lakhai, J.M.; van den Bongard, D.; Pluim, D.; Beijnen, J.H.; Schellens, J.H. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res., 2004, 10, 3717-3727.
80. Heffeter, P.; Jungwirth, U.; Jakupec, M.; Hartinger, C.; Galanski, M.; Elbling, L.L.; Micksche, M.; Keppler, B.; Berger, W. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist. Update, 2008, 11, 1-16.
81. Antonarakis, E.S.; Emadi, A. Ruthenium-based chemotherapeutics: are they ready for prime time? Cancer Chemother. Pharmacol., 2010, 66, 1-9.
82. Reisner, E.; Arion, V.B.; Keppler, B.K.; Pombeiro, A.J.L. Electrontransfer activated metal-based anticancer drugs. Inorg. Chim. Acta, 2008, 361, 1569-1583.
83. Sava, G.; Bergamo, A. Ruthenium-based compounds and tumour growth control (review). Int. J. Oncol., 2000, 17, 353-365.
84. Giovagnini, L.; Sitran, S.; Castagliuolo, I.; Brun, P.; Corsini, M.; Zanello, P.; Zoleo, A.; Maniero, A.; Biondi, B.; Fregona, D. Ru(III)-based compounds with sulfur donor ligands: synthesis, characterization, electrochemical behaviour and anticancer activity. Dalton Trans., 2008, 6699-6708.
85. Giovagnini, L.; Mancinetti, E.; Ronconi, L.; Sitran, S.; Marchiò, L.; Castagliuolo, I.; Brun, P.; Trevisan, A.; Fregona, D. Preliminary chemico-biological studies on Ru(III) compounds with S-methyl pyrrolidine/dimethyl dithiocarbamate. J. Inorg. Biochem., 2009, 103, 774-782.
86. Nagy, E.M.; Nardon, C.; Giovagnini, L.; Marchiò, L.; Trevisan, A.; Fregona, D. Promising anticancer mono- and dinuclear ruthenium(III) dithiocarbamato complexes: systematic solution studies. Dalton Trans., 2011, 40, 11885-11895.
87. Mattson, B.M.; Heiman, J.R.; Pignolet, L.H. Oxidation of tris(N,Ndisubstituted-dithiocarbamato) complexes of ruthenium(III). X-ray structure determination of bis(N,N-diethyldithiocarbamato)- μ-tris(N,N-diethyldithiocarbamato)-diruthenium(III) tetrafluoroborate, [Ru2(Et2dtc)5]BF4. Inorg. Chem., 1976, 15, 564-571.
88. Zhao, H.; Ning, Y. China's ancient gold drugs. Gold Bull., 2001, 34, 24-29.
89. Benedek, T. G. The history of gold therapy for tuberculosis. J. Hist. Med. All. Sci., 2004, 59, 50-89.
90. Kean, W.F.; Kean, I.R.L. Clinical pharmacology of gold. Inflammopharmacology, 2008, 16, 112-125.
91. Mirabelli, C.K.; Johnson, R.K.; Sung, C.M.; Faucette, L.; Muirhead, K.; Crooke, S.T. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res., 1985, 45, 32-39.
92. Aldinucci, D.; Ronconi, L.; Fregona, D. Groundbreaking gold(III) anticancer agents. Drug Discov. Today, 2009, 14, 1075-1076.
93. Che, C.-M.; Sun, R.W.-Y. Therapeutic applications of gold complexes: lipophilic gold(III) cations and gold(I) complexes for anti-cancer treatment. Chem. Commun., 2011, 47, 9554-9560.
94. Todd, R.C.; Lippard, S.J. Inhibition of transcription by platinum antitumor compounds. Metallomics, 2009, 1, 280-291.
95. Ronconi, L.; Aldinucci, D.; Dou, Q.P.; Fregona, D. Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes. Anti-Cancer Agents Med. Chem., 2010, 10, 283-292.
96. Ronconi, L.; Marzano, C.; Zanello, P.; Corsini, M.; Miolo, G.; Maccà, C.; Trevisan, A.; Fregona, D. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. J. Med. Chem., 2006, 49, 1648-1657.
97. Koelle, U.; Laguna, A. Electrochemistry of Au-complexes. Inorg. Chim. Acta, 1999, 290, 44-50.
98. Ronconi, L.; Giovagnini, L.; Marzano, C.; Bettio, F.; Graziani, R.; Pilloni, G.; Fregona, D. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties and in vitro antitumor activity. Inorg. Chem., 2005, 44, 1867-1881.
99. Giovagnini, L.; Ronconi, L.; Aldinucci, D.; Lorenzon, D.; Sitran, S.; Fregona, D. Synthesis, characterization and comparative in vitro cytotoxicity studies of platinum(II), palladium(II) and gold(III) methylsarcosinedithiocarbamate complexes. J. Med. Chem., 2005, 48, 1588-1595.
100. Aldinucci, D.; Lorenzon, D.; Stefani, L.; Giovagnini, L.; Colombatti, A.; Fregona, D. Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro. Anti-Cancer Drugs, 2007, 18, 323-332.
101. Bindoli, A.; Rigobello, M.P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev., 2009, 253, 1692-1707.
102. Saggioro, D.; Rigobello, M.P.; Paloschi, L.; Folda, A.; Moggach, S.A.; Parsons, S.; Ronconi, L.; Fregona, D.; Bindoli, A. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway. Chem. Biol., 2007, 14, 1128-1139.
103. Milacic, V.; Chen, D.; Ronconi, L.; Landis-Piwowar, K.R.; Fregona, D.; Dou, Q.P. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res., 2006, 66, 10478-10486.
104. Zhang, X.; Frezza, M.; Milacic, V.; Ronconi, L.; Fan, Y.; Bi, C.; Fregona, D.; Dou, Q.P. Inhibition of tumor proteasome activity by gold dithiocarbamato complexes via both redox-dependent and - independent processes. J. Cell. Biochem., 2010, 109, 162-172.
105. Perez-Galan, P.; Roue, G.; Villamar, N.; Montserrat, E.; Campo, E.; Colomer, D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107, 257-264.
106. Casini, A.; Kelter, G.; Gabbiani, C.; Cinellu, M.A.; Minghetti, G.; Fregona, D.; Fiebig, H.H.; Messori, L. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J. Biol. Inorg. Chem., 2009, 14, 1139-1149.
107. Rubio-Aliaga, I.; Daniel, H. Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica, 2008, 38, 1022-1042.
108. Brandsch, M.; Knütter, I.; Bosse-Doenecke, E. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol., 2008, 60, 543-585.
109. Brandsch, M. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin. Drug Metab. Toxicol., 2009, 5, 887-905.
110. Negom Kouodom, M.; Ronconi, L.; Celegato, M.; Nardon, C.; Marchiò, L.; Dou, Q.P.; Aldinucci, D.; Formaggio, F.; Fregona, D. Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics. J. Med. Chem., 2012, 55, 2212-2226.
111. Fregona, D.; Ronconi, L.; Formaggio, F.; Dou, Q. P.; Aldinucci, D. Gold(III) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents. PCT Int. Appl., 2010, WO2010105691A1.